WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 28-May-2015 (Data received as of 22-May-2015)
Next overall update July 2015
2014 data are provisional
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 102
GDP / capita (US$): 44'0521 Child (under 5 years) mortality rate: 122

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 3'926  3'632  3'314  3'025  2'803  2'193  1'810  1'154 
Births 75  74  72  70  67  54  69  58 
Surviving infants 75  74  72  69  66  53  67  54 
Pop. less than 5 years 367  353  333  312  295  270  323  230 
Pop. less than 15 years 889  853  814  784  768  815  820  520 
Female 15-49 years 819  780  739  702  674  483  328  237 

Number of reported case

(Click for retrospective incidence data for Oman)
Diphtheria
Japanese encephalitis
Measles 13  15  1'262  10'630 
Mumps 202  163  679  121  575  10'443 
Pertussis 165  309  165  88  32  190  49  1'534 
Polio* 37 
Rubella 13 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)** 48 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Oman)
Vaccine year result method % card seen                                                
BCG 1994  100  FHS   95  99*  99*  99*  99*  99  98  96  51 
DTP1 1994  100  FHS   95  99*  99*  99  99*  99*  98 
DTP3 1994  98  FHS   95  97  98  98  99*  99  99*  98  18 
HepB_BD          99*  99*  99*  99  99*  99 
HepB3 1994  98  FHS   95  97  98  98  99*  99  99* 
Hib3          97  98  98  99*  99 
JapEnc         
MCV 1994  98  FHS   95  99*  99*  99*  99*  99*  99*  98  22 
MCV2          99  99*  99*  99  99  99* 
PCV1          99*  99*  98  99  99* 
PCV3          98  99  99*  99  99* 
Pol3 1994  98  FHS   95  99  99*  99  99*  99  99*  98  18 
Rota1         
Rota_last         
Rubella1          99*  99*  99*  99*  99* 
TT2plus          66  67  71  68  70  44  97  39 
PAB         
VAD1          99*  96  96  98  98  99* 
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Oman)
BCG 99  99  99  99  98  96  51 
DTP1 99  99  99  99  99  98  41 
DTP3 98  98  99  99  99  98  18 
HepB3 97  97  99  98  99 
HepB_BD 99  99  99  99  99 
Hib3 98  98  99  99 
MCV 99  99  99  99  99  98  22 
MCV2 99  99  99  99  99 
PAB 91  91  91  91  94  93  35 
PCV3 99  99  99  99 
Pol3 99  99  99  99  99  98  18 
Rota_last

Number of districts in the country 61  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DT 6 years; Yes
DTwP 18 months; Yes
DTwPHibHepB 2, 4, 6 months;
DTwPHibHepBIPV 2 months;
HepB birth; Yes
IPV 9 weeks;
Influenza Yes adults
MMR 12, 18 months; 35-49 years;
OPV 4, 6, 18 months; 6, 18 years; Yes
Pneumo_conj 2, 4, 13 months; Yes
Rabies Yes high risks (animal bites)
TT Yes Pregnant /Wound
Td 12, 17 years; Yes
Typhoid Yes food handlers
Varicella 12 months; Yes
VitaminA 9, 18 months; Yes and to post-partum women within 15 days of delivery
YF Yes visiting eligible countries

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2011-2015  2011-2015  2011-2015  2011-2015  2011-2015  2006-2010  2006-2010 
Nº of districts with microplans that include activities to raise immunization coverage number 61             

System performance

Total Nº districts in country number 61  61  61  61  61  61  61 
Nº districts with DTP3 coverage >=80% number 61  61  61  61  61  61  61 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 61  61  61  61  61  61  61 
% of districts with MCV1 coverage >=95% From 0 to 100% 100  100  100  100  100  100  100 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%           100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.